ChinaAMC Health Mix A Posts Q2 Profit of 15.31 Million Yuan, NAV Up 4.48%

Earnings
โดย 中国证券报·Read original
Summary · why it matters

ChinaAMC Health Mix A disclosed its second-quarter 2026 report, with a quarterly profit of 15.3123 million yuan and a net asset value growth rate of 4.48%. As of the end of the second quarter, the fund size stood at 374 million yuan. Fund manager Sun Mingda stated that during the quarter, the fund continued to increase holdings in innovative drug assets and the pharmaceutical outsourcing services sector, where fundamentals are steadily recovering. The portfolio tilted moderately toward innovation, and going forward, asset allocation will continue to center on two core themes: rigid domestic demand and industrial innovation and upgrading. As of July 21, the fund's three-month cumulative NAV growth rate was 8.21%, ranking 20th out of 127 comparable funds. Its one-year growth rate was 2.28%, ranking 30th out of 127, and its three-year growth rate was 27.88%, ranking 27th out of 102. The fund's three-year Sharpe ratio was 0.3133, with a maximum drawdown of 26.62% and an average equity position of 85.01%. At the end of the second quarter, the top ten heavy-weighted holdings included Kelun Pharmaceutical, RemeGen, and Hengrui Medicine.

Impact on stocks 4

Others▲ · 4 stocks
RemeGen Co. Ltd. A
688331
▲ PositiveDemandrelevance

Fund increased holdings in innovative drug assets, including RemeGen, indicating positive demand outlook.

© 2026 MarketDXNews